JP2017511322A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511322A5
JP2017511322A5 JP2016559891A JP2016559891A JP2017511322A5 JP 2017511322 A5 JP2017511322 A5 JP 2017511322A5 JP 2016559891 A JP2016559891 A JP 2016559891A JP 2016559891 A JP2016559891 A JP 2016559891A JP 2017511322 A5 JP2017511322 A5 JP 2017511322A5
Authority
JP
Japan
Prior art keywords
conjugate
moiety
soluble polymer
water
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559891A
Other languages
English (en)
Japanese (ja)
Other versions
JP6728055B2 (ja
JP2017511322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023871 external-priority patent/WO2015153753A2/en
Publication of JP2017511322A publication Critical patent/JP2017511322A/ja
Publication of JP2017511322A5 publication Critical patent/JP2017511322A5/ja
Application granted granted Critical
Publication of JP6728055B2 publication Critical patent/JP6728055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559891A 2014-04-03 2015-04-01 Il−15部分とポリマーとのコンジュゲート Active JP6728055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03
US61/974,914 2014-04-03
PCT/US2015/023871 WO2015153753A2 (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020074680A Division JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2017511322A JP2017511322A (ja) 2017-04-20
JP2017511322A5 true JP2017511322A5 (enExample) 2018-04-12
JP6728055B2 JP6728055B2 (ja) 2020-07-22

Family

ID=54241432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559891A Active JP6728055B2 (ja) 2014-04-03 2015-04-01 Il−15部分とポリマーとのコンジュゲート
JP2020074680A Withdrawn JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020074680A Withdrawn JP2020114875A (ja) 2014-04-03 2020-04-20 Il−15部分とポリマーとのコンジュゲート

Country Status (12)

Country Link
US (1) US20170035898A1 (enExample)
EP (2) EP3919071A1 (enExample)
JP (2) JP6728055B2 (enExample)
KR (1) KR102432169B1 (enExample)
CN (1) CN106456716A (enExample)
AU (3) AU2015240806B2 (enExample)
CA (1) CA2942571C (enExample)
ES (1) ES2876433T3 (enExample)
IL (1) IL248169A0 (enExample)
MA (1) MA39711A (enExample)
MX (2) MX388865B (enExample)
WO (1) WO2015153753A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
EP3206713A4 (en) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
KR20250057110A (ko) * 2017-05-15 2025-04-28 넥타르 테라퓨틱스 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
AU2019224159B2 (en) * 2018-02-26 2025-05-29 Sanofi IL-15 conjugates and uses thereof
JP7611136B2 (ja) * 2018-11-09 2025-01-09 ネクター セラピューティクス 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン-15受容体作動薬
WO2020219943A1 (en) * 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
WO2020247388A2 (en) 2019-06-03 2020-12-10 Medikine, Inc. Il-2alpha receptor subunit binding compounds
CA3148135A1 (en) * 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
KR20240004403A (ko) * 2021-03-29 2024-01-11 오디 쎄라퓨틱스 리미티드 단백질-거대분자 접합체 및 이의 사용 방법
JP2024526080A (ja) 2021-06-23 2024-07-17 サイチューン ファーマ インターロイキン15多様体
US20250270273A1 (en) * 2021-07-12 2025-08-28 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (en) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Prostate-specific membrane antigen (psma)-binding peptides and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
US20060057680A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
US20060104945A1 (en) 2004-10-05 2006-05-18 Choi Yong S Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
CN106046370A (zh) 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
JP5775820B2 (ja) * 2008-10-21 2015-09-09 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 遊離可能peg試薬を有するプロドラッグpegタンパク質結合体において活性成分(インビトロ脱ペグ化)を決定する方法
TWI534152B (zh) * 2010-07-30 2016-05-21 巴克斯特國際公司 用於肟連接的親核性催化劑
ES2866674T3 (es) * 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Similar Documents

Publication Publication Date Title
JP2018510863A5 (enExample)
Franck et al. Biopolymer‐based carriers for DNA vaccine design
HRP20210642T1 (hr) Konjugati il-2 ostatka i polimera
JP2006519238A5 (enExample)
Wong et al. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo
Birke et al. Polypeptoid-block-polypeptide copolymers: Synthesis, characterization, and application of amphiphilic block copolypept (o) ides in drug formulations and miniemulsion techniques
IL170424A (en) Compositions containing conjugates of a polymer and a factor viii moiety
WO2009021017A3 (en) Nucleic acid-lipopolymer compositions
Kloeckner et al. Gene carriers based on hexanediol diacrylate linked oligoethylenimine: effect of chemical structure of polymer on biological properties
Abebe et al. Three‐layered biodegradable micelles prepared by two‐step self‐assembly of PLA‐PEI‐PLA and PLA‐PEG‐PLA triblock copolymers as efficient gene delivery system
EP3549963A3 (en) High molecular weight zwitterion-containing polymers
Heller et al. Directed Interactions of Block Copolypept (o) ides with Mannose‐binding Receptors: PeptoMicelles Targeted to Cells of the Innate Immune System
WO2011112482A3 (en) Polymeric drug delivery conjugates and methods of making and using thereof
JP2011528654A5 (enExample)
JP2011530597A5 (enExample)
Cunningham et al. New Design of Thiol‐Responsive Degradable Polylactide‐Based Block Copolymer Micelles
JP2011080089A5 (enExample)
JP2005520006A5 (enExample)
JP2013519636A5 (enExample)
ES2721850T3 (es) Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
WO2010005740A3 (en) Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
WO2012054923A3 (en) Therapeutic nanoparticles with high molecular weight copolymers
JP2014058562A5 (enExample)
Soni et al. Biodegradable block copolymers and their applications for drug delivery
JP2014501765A5 (enExample)